Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiol Therapeutics (CRDL) Profit After Tax (2020 - 2026)

Cardiol Therapeutics filings provide 2 years of Profit After Tax readings, the most recent being -$5.5 million for Q4 2022.

  • On a quarterly basis, Profit After Tax fell 11.52% to -$5.5 million in Q4 2022 year-over-year; TTM through Dec 2022 was -$23.8 million, a 5.58% increase, with the full-year FY2025 number at -$24.2 million, up 9.65% from a year prior.
  • Profit After Tax hit -$5.5 million in Q4 2022 for Cardiol Therapeutics, up from -$6.1 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$5.0 million in Q4 2021 to a low of -$7.9 million in Q3 2021.